RASD1 suppresses GM-CSF signaling network to confer immunosuppressive tumor microenvironment
The goal of this study is to investigate the role of RASD1 in promoting tumor progression and immune evasion, with a specific focus on its effects in modulating the tumor microenvironment. Using syngeneic mouse models and single-cell RNA sequencing (scRNA-seq), the study aims to uncover how RASD1 overexpression influences immune cell composition, particularly the increase in myeloid-derived suppressor cells (MDSCs) and M2 macrophages, which contribute to immunotherapy resistance. By examining the effects of RASD1 knockdown and combining GM-CSF with anti-PD1 therapy, the study seeks to identify potential therapeutic strategies to overcome treatment-refractory tumors. The findings are highly relevant for advancing cancer immunotherapy, as they provide insights into molecular targets that could enhance the efficacy of current therapies, particularly in tumors resistant to immunotherapy.